Brain, Vol. 125, No. 9, 2058-2066,
September 2002
© 2002 Guarantors of Brain
Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease
1 Institute of Neurology IRCCS ‘Neuromed’ (15), 2 University La Sapienza, Rome, Italy and 3 Department of Neurology, Mount Sinai School of Medicine, New York, USA
Correspondence to: Dr Fabrizio Stocchi, Department of Neuroscience and ‘Neuromed’, University La Sapienza, Viale dell’Universita’ 30, 00185 Roma, Italy E-mail: fabstocc{at}tin.it
Motor complications are a major source of disability for patients with advanced Parkinson’s disease. Surgical therapies provide benefit to some, but these treatments are expensive and associated with adverse effects. Current research indicates that motor complications are associated with abnormal, intermittent, pulsatile stimulation of denervated dopamine receptors using short acting dopaminergic agents such as levodopa. Retrospective studies suggest that the use of longer-acting more continuous dopaminergic therapies can improve both motor fluctuations and dyskinesia. We performed a prospective, long-term (4-year) trial comparing patients randomized to receive subcutaneous infusion of the dopamine agonist lisuride versus conventional therapy with oral levodopa and dopamine agonists. We demonstrate that patients receiving lisuride infusions experienced a significant reduction in both motor fluctuations and dyskinesia compared with patients receiving standard dopaminergic therapies. Benefits persisted for the 4-year duration of the study. Mean Unified Parkinson’s Disease Rating Scale scores in ‘ON’ and ‘OFF’ states did not significantly change between baseline and 4 years for patients in the lisuride group, but deteriorated in patients in the levodopa group. This study indicates that continuous lisuride infusion can be beneficial for patients with advanced Parkinson’s disease and reverse established motor fluctuations and dyskinesia.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Linazasoro Pathophysiology of Motor Complications in Parkinson Disease: Postsynaptic Mechanisms Are Crucial Arch Neurol, January 1, 2007; 64(1): 137 - 140. [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Pfeiffer A promising new technology for Parkinson's disease Neurology, July 26, 2005; 65(2_suppl_1): S6 - S10. [Full Text]
|
|
|
|
|
|
W. Poewe and F. Luessi Clinical studies with transdermal rotigotine in early Parkinson's disease Neurology, July 26, 2005; 65(2_suppl_1): S11 - S14. [Full Text]
|
|
|
|
|
|
F. Stocchi, L. Vacca, S. Ruggieri, and C. W. Olanow Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease: A Clinical and Pharmacokinetic Study Arch Neurol, June 1, 2005; 62(6): 905 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Carlsson, C. Winkler, C. Burger, N. Muzyczka, R. J. Mandel, A. Cenci, A. Bjorklund, and D. Kirik Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors Brain, March 1, 2005; 128(3): 559 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Mouradian Should levodopa be infused into the duodenum? Neurology, January 25, 2005; 64(2): 182 - 183. [Full Text] [PDF]
|
|
|
|
|
|
D. Nyholm, A. I.M. Nilsson Remahl, N. Dizdar, R. Constantinescu, B. Holmberg, R. Jansson, S. -M. Aquilonius, and H. Askmark Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease Neurology, January 25, 2005; 64(2): 216 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B R Thanvi and T C N Lo Long term motor complications of levodopa: clinical features, mechanisms, and management strategies Postgrad. Med. J., August 1, 2004; 80(946): 452 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Bakker, D. M. Weiner, T. ter Laak, T. Beuming, O. P. Zuiderveld, M. Edelbroek, U. Hacksell, H. Timmerman, M. R. Brann, and R. Leurs 8R-Lisuride Is a Potent Stereospecific Histamine H1-Receptor Partial Agonist Mol. Pharmacol., March 1, 2004; 65(3): 538 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Stocchi and C. W. Olanow Continuous dopaminergic stimulation in early and advanced Parkinson's disease Neurology, January 13, 2004; 62(90011): S56 - 63. [Abstract] [Full Text]
|
|
|
|
|
|
C. W. Olanow and F. Stocchi COMT inhibitors in Parkinson's disease: Can they prevent and/or reverse levodopa-induced motor complications? Neurology, January 13, 2004; 62(90011): S72 - 81. [Abstract] [Full Text]
|
|
|
|
|
|
C. W. Olanow Present and future directions in the management of motor complications in patients with advanced PD Neurology, September 23, 2003; 61(90063): S24 - 33. [Full Text]
|
|